Business
Avanos sells medical device products across Specialty Nutrition Systems and Pain Management and Recovery, including enteral feeding and radiofrequency ablation products.
Avanos revenue rose and losses narrowed, but free cash flow fell, margins were mixed, and Altman-Z was distressed.
The read at a glance✓ Audited against SEC data
- Business mix — Specialty nutrition and pain recovery devicesNote
- Revenue — Revenue rose 1.9%OK
- Losses — Net loss narrowed to $72.9MOK
- Cash — FCF fell 48.0%Watch
- Debt — Debt fell 27.9%OK
- Insiders — 1 buy / 1 sellNote
- Accounting — Altman-Z distress; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as AVANOS MEDICAL, INC. reports it. History and quarterly detail are in the app.
- Total Specialty Nutrition Systems$432.9M
- Total Pain Management and Recovery$237.8M
- Corporate and other$30.5M
Leadership changes
From AVANOS MEDICAL, INC.'s own filings, the day they're filed.
- Kerr Holbrook · Chief Commercial Officer · departureeff. 2025-12-01
- Mojirade James · President · departureeff. 2025-12-01
- Michael C. Greiner · departureeff. 2025-04-28
Latest filings
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-07-15
- 8-K · Company announcement2026-07-02
- 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AVANOS MEDICAL, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.